[212Pb]Pb-212-F3-C25

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 28104527: 'TCMC-mAb F3-C25'. Stage 25: this agent has NO own synthesis/characterisation data in the current corpus -- the model's own extraction reasoning confirms F3-C25 appears in every linked article solely as a non-targeting isotype-control antibody compared against the real therapeutic agents (212Pb-376.96, 212Pb-225.28) -- never characterised itself. All previously-linked runs were unlinked (see parsed-therapy.xlsx). Stage set/updated at stage 39 from PMID 28104527: 'These results support additional RIT studies with 212Pb-376.96 for future evaluation in patients with ovarian cancer.'.